Checkpoint Therapeutics, Inc(NASDAQ:CKPT) 
Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal ...
Website: http://www.checkpointtx.com
Founded: 2014
Full Time Employees: 8
CEO: James Oliviero
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2024-11-27
P
O 4.10
H 4.32
L 4.05
C 4.28
V 971,994
10EMA 4.28
20EMA 4.28
60EMA 4.28
120EMA 4.28
250EMA 4.28